Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Elizabeth A. Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine · 1982 · 2.2K citations · Full text

Life Sciences, Immunology, Oncology +15

lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis

Michael J. Lenardo · Nature · 1991 · 1K citations

Life Sciences, Cell Biology, Immunology +13

Comparative studies of human FcRIII-positive and negative natural killer cells.

Arnon Nagler, Lewis L. Lanier, Steven E. Cwirla et al. · The Journal of Immunology · 1989 · 683 citations · Full text

Life Sciences, Cell Biology, Immunology +14

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Michael T. Lotze, Yvedt L. Matory, Stephen E. Ettinghausen et al. · The Journal of Immunology · 1985 · 614 citations

Life Sciences, Immunology, Pharmacology +9

Transient expression of interleukin 2 receptors. Consequences for T cell growth.

Doreen A. Cantrell, Kendall A. Smith · The Journal of Experimental Medicine · 1983 · 611 citations · Full text

Life Sciences, Cell Biology, Immunology +15